Gene TechnoScience

Basic Information

Stock Code
4584
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
March 2001
Listing Year
November 2012
Official Website
https://www.g-gts.com/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNI Group, Heartseed, AxelMark, Social Wire, Ecomot, Nexel Pharma, PeptiDream, Ribomic, SanBio, Helios, FANPEP, Perseus Proteomics, RenaScience, Tsukada Lab, QualiPS, Takara Bio, ReproCELL, Architects Studio Japan, PhoenixBio, Japan Tissue Engineering

Overview

Gene TechnoScience is a bio-pharmaceutical company founded in 2001, focusing on new drug development and generic drug manufacturing using gene modification technology in collaboration with Hokkaido University.

Current Situation

Gene TechnoScience maintained a solid R&D structure in fiscal 2023, recording sales of approximately 5 billion yen. Through joint research with Hokkaido University, it has developed advanced gene modification technology, aiming for new drug creation while also focusing on the generic pharmaceuticals market. In its core bio-pharmaceutical development, it leverages high technological capabilities and strives to improve pharmaceutical quality. It actively raises funds through stock acquisition rights issuance and others to promote R&D investments. In recent years, it has focused on regulatory compliance and strengthening quality management systems, working on optimization of pharmaceutical manufacturing processes. Moving forward, in addition to expanding sales of generics domestically and internationally, it aims to accelerate clinical development of new drug candidates and enhance corporate value. On the sustainability front, it advances R&D that reduces environmental impact and strengthens its posture in fulfilling social responsibilities. In the future, it plans to continue growing by actively entering domestic and international markets with manufacturing and sales of innovative pharmaceuticals.

Trivia

Interesting Facts

  • Venture established through joint research with Hokkaido University.
  • Pioneering company applying gene modification technology to pharmaceutical development.
  • Rare entity handling both generics and drug discovery areas.
  • Actively raising funds through stock acquisition rights issuance.
  • Successfully established long-term quality management system.
  • Holds numerous bio-related patents.
  • Based in Tokyo with close collaboration with Hokkaido University.
  • Recognized as a promising growth company in the bio drug discovery industry.
  • Initiated R&D of gene editing tools.
  • High-quality contract manufacturing services as a strength.
  • Corporate culture enthusiastic about nurturing young researchers.
  • Diverse bio pharmaceutical products.
  • Strong partnerships with domestic and international medical institutions.
  • Possesses CLIA-certified analysis equipment.
  • Introduced in-house environmentally considerate production lines.

Hidden Connections

  • Established proprietary technology through joint research with Hokkaido University, differentiating from competitors.
  • Maintains close transaction relationships with major suppliers in the domestic generics market.
  • Participates in support activities for biotechnology-related startups.
  • Forms joint clinical development partnerships with domestic and international pharmaceutical companies.
  • Gene-modified antibody technology implemented in collaboration with multiple university research groups in Japan.
  • Some pharmaceutical contract manufacturing built in collaboration with overseas bases.
  • Received high evaluations in the industry for sustainability indicator reporting.
  • Researching drug discovery support technology using artificial intelligence.

Future Outlook

Growth Drivers

  • Steady growth in domestic generic pharmaceuticals market.
  • Increase in new drug development using gene modification technology.
  • Product development responding to diversifying medical needs.
  • Market entry through regulatory easing and accelerated clinical trials.
  • Global expansion of bio pharmaceutical demand.
  • Technological innovation from increased R&D investments.
  • Expansion of drug discovery applications for advanced technologies like AI.
  • Competitive strengthening through stricter quality management.
  • Expansion of domestic and international partnerships.
  • Corporate value enhancement through sustainability measures.
  • Development of pharmaceuticals responding to growing chronic disease needs.
  • Sales expansion using digital platforms.

Strategic Goals

  • Improvement in new drug clinical development success rate.
  • Expansion of domestic share in generic pharmaceuticals market.
  • Active entry into global markets.
  • Realization of zero-environmental-impact manufacturing processes.
  • Acquisition of international certifications for bio pharmaceutical research facilities.
  • Completion of advanced quality assurance system.
  • Expansion of product lineup responding to diverse medical needs.
  • Achievement of drug discovery efficiency improvement using AI.
  • Establishment of sustainable procurement and production systems.
  • Promotion of diversity in R&D staff.

Business Segments

Pharmaceutical Development Support

Overview
Provides drug discovery support services using gene technology to accelerate pharmaceutical development.
Competitiveness
High-precision technology through collaboration with Hokkaido University
Customers
  • Major Pharmaceutical Companies
  • Bio Ventures
  • Research Institutions
  • University Labs
  • CRO (Contract Research Organizations)
Products
  • Gene Modification Technology Services
  • Research Reagents
  • Animal Model Provision
  • Clinical Trial Drug Manufacturing

Generic Pharmaceutical Manufacturing

Overview
Manufactures and supplies high-quality generic pharmaceuticals to support cost reduction.
Competitiveness
Advanced quality management and stable supply system
Customers
  • Generic Pharmaceutical Wholesalers
  • Hospital Pharmacies
  • Drugstores
  • Medical Corporations
Products
  • Generic Tablets
  • Bio Generics
  • Formulation Development
  • Quality Management Support

Research Reagent Sales

Overview
Provides a wide variety of research reagents for bio pharmaceuticals.
Competitiveness
Custom response tailored to researchers' needs
Customers
  • University Research Institutions
  • Pharmaceutical Company R&D Departments
  • Bio Ventures
  • Hospital Labs
Products
  • Gene Analysis Reagents
  • Protein Production Kits
  • Cell Culture Materials
  • Enzyme Reagents

Contract Manufacturing Services

Overview
High-quality services for bio pharmaceutical contract manufacturing and quality management.
Competitiveness
Flexible manufacturing lines and advanced quality management system
Customers
  • Small and Medium Pharmaceutical Companies
  • Startups
  • Research Institutions
  • Overseas Companies
Products
  • Pharmaceutical Manufacturing Contracts
  • Analysis Services
  • Quality Assurance
  • Technology Transfer Support

Competitive Advantage

Strengths

  • Strong research collaboration with Hokkaido University
  • High expertise in gene modification technology
  • Stable production capacity in generics field
  • Drug discovery capabilities leveraging latest technologies
  • Thorough quality management system
  • Diverse product lineup
  • Promotion of R&D through active fundraising
  • Good relationships with domestic medical institutions
  • Contract manufacturing service capabilities
  • Collaboration experience with pharmaceutical companies
  • High customer satisfaction
  • Compliance with laws and regulations
  • Rapid market response capabilities
  • Comprehensive clinical development support system
  • Flexible reagent customization

Competitive Advantages

  • Innovative technology development through collaboration with academic research institutions
  • Diverse pharmaceutical lineup based on gene modification technology
  • High-quality manufacturing capabilities in generic pharmaceuticals market
  • Differentiation through specialized contract manufacturing services
  • Product stability ensured by multi-stage quality management
  • Strengthened fundraising through stock acquisition rights issuance
  • Legal system prepared to comply with domestic and international regulations
  • Rapid formulation development and clinical trial response
  • Customization proposal capabilities for research reagents
  • Long-term partnership potential backed by advanced technology
  • Flexible product development in response to changing market needs
  • Wide sales channels for diverse customer segments
  • Expertise in pharmaceutical safety testing
  • Patent portfolio differentiating from competitors
  • Reliability as a Hokkaido University spin-off venture

Threats

  • Development delays due to stricter pharmaceutical regulations
  • Intensifying price competition with domestic and international rivals
  • Market saturation in generic pharmaceuticals
  • Technology obsolescence risk from rapid technological innovation
  • Market pressure from emerging new entrants
  • Patent-related litigation risks
  • Financial strain from rising R&D costs
  • Product recall risks from quality issues
  • Business constraints from legal system changes
  • Challenges in global market expansion
  • Revenue fluctuation risks from exchange rate changes
  • Clinical trial failure risks

Innovations

2024: Accelerating Development of Gene-Modified Antibody Drugs

Overview
Started clinical development of new antibody drugs using gene modification technology.
Impact
Strengthening foundation for new drug creation

2023: Expansion of Generic Pharmaceutical Manufacturing Facilities

Overview
Expanded production lines for generics to increase supply capacity.
Impact
Stable product supply and improved market share

2022: Launch of High-Precision Gene Analysis Kit

Overview
Introduced new series of research gene analysis kits.
Impact
Strengthening contract research services

2021: Introduction of Low-Environmental-Impact Manufacturing Process

Overview
Achieved energy savings and waste reduction in pharmaceutical processes.
Impact
Establishment of sustainable production system

2020: Patent Acquisition for Drug Discovery Candidate Compounds

Overview
Acquired patents for new anti-cancer agent candidates domestically and internationally.
Impact
Strengthening intellectual property of proprietary technology

Sustainability

  • Promotion of environmentally considerate manufacturing processes
  • Operation start of energy-saving research facilities
  • Improvement in waste reduction and recycling rates
  • Workplace environment improvement emphasizing employee health and safety
  • Active participation in regional medical support activities
  • Thorough ethical bio research
  • Promotion of highly transparent information disclosure
  • Formulation of sustainable procurement policies
  • Promotion of gender equality and diversity
  • Cooperation in regional environmental conservation activities
  • Promotion of awareness reform through in-house education
  • Proper disposal of pharmaceutical waste